PCV regimen

chemotherapy protocol consisting of the above cpds; used in treatment of resectable bronchogenic non-small cell carcinoma

Networked: 9 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - PCV regimen: 9
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - PCV regimen: 9
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - PCV regimen: 9
Inorganic Chemicals: 9
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Halogenated Hydrocarbons: 42
    - Mustard Compounds: 3
      - Nitrogen Mustard Compounds: 2
        Phosphoramide Mustards: 5
        Cyclophosphamide: 25473
        PCV regimen: 9
- Organophosphorus Compounds: 300
  - Phosphoramides: 8
    - Phosphoramide Mustards: 5
      - Cyclophosphamide: 25473
        PCV regimen: 9
Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Secologanin Tryptamine Alkaloids: 81
      - Vinca Alkaloids: 463
        Vindesine: 836
        PCV regimen: 9
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vindesine: 836
        PCV regimen: 9
    - Indolizines: 3
      - Indolizidines: 2
        Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vindesine: 836
        PCV regimen: 9

Experts

1.	Le Rhun, Emilie: 1 article (07/2020)
2.	Weller, Michael: 1 article (07/2020)
3.	Bahary, Jean-Paul: 1 article (05/2017)
4.	Bettegowda, Chetan: 1 article (05/2017)
5.	Cairncross, Gregory J: 1 article (05/2017)
6.	Chakravarti, Arnab: 1 article (05/2017)
7.	Hartford, Alan C: 1 article (05/2017)
8.	Holdhoff, Matthias: 1 article (05/2017)
9.	Jenkins, Robert B: 1 article (05/2017)
10.	Kinzler, Kenneth: 1 article (05/2017)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2015 - "Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen." 05/01/1998 - "We advocate to use the standard PCV regimen in patients with recurrent glioma, because of this potential toxicity and the lack of evidence that intensive PCV leads to better tumor control than standard PCV in cerebral glioma." 10/01/2000 - "The addition of DFMO to the nitrosourea-based PCV regimen in this phase III study demonstrated no additional benefit in glioblastoma patients, underscoring the resistance of glioblastoma multiforme tumors to alkylating agents. " 07/01/2020 - "The most compelling data for lomustine stem from three randomized trials when lomustine was combined with procarbazine and vincristine as the PCV regimen in the newly diagnosed setting together with radiotherapy; improved survival with PCV was restricted to patients with isocitrate dehydrogenase-mutant tumors. "
2.	Oligodendroglioma 05/30/2017 - "The NRG Oncology RTOG 9402 trial showed significant survival benefit in patients with 1p/19q co-deleted anaplastic oligodendrogliomas (AO) who received both radiation (RT) and chemotherapy (PCV regimen) versus RT alone. " 11/01/1998 - "A Phase II study was conducted to determine the benefits and toxicity of the procarbazine, lomustine, and vincristine (PCV) regimen in patients with low-grade oligodendrogliomas and oligoastrocytomas recurrent after surgery alone or surgery with radiotherapy. "
3.	Glioblastoma (Glioblastoma Multiforme) 10/01/2000 - "The addition of DFMO to the nitrosourea-based PCV regimen in this phase III study demonstrated no additional benefit in glioblastoma patients, underscoring the resistance of glioblastoma multiforme tumors to alkylating agents. "
4.	Glioma (Gliomas) 05/01/1998 - "We advocate to use the standard PCV regimen in patients with recurrent glioma, because of this potential toxicity and the lack of evidence that intensive PCV leads to better tumor control than standard PCV in cerebral glioma." 06/01/2002 - "Overall survival and progression-free survival after 5 and 10 years of 31 patients with malignant glioma treated by a combination of surgery, postoperative radiotherapy, and chemotherapy with a PCV regimen (procarbazine, CCNU [lomustine] and vincristine) is described. "
5.	Central Nervous System Neoplasms 02/01/2017 - "Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors."

Related Drugs and Biologics

1.	Vincristine (Oncovin)
2.	Procarbazine (Matulane)
3.	Lomustine (CCNU)
4.	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))
5.	Alkylating Agents

Related Therapies and Procedures

1.	Radiotherapy
2.	Drug Therapy (Chemotherapy)